ArticleInfectious diseases and therapy2023

Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia".

No numbers read from the abstract.

Not cited yet